YD Bio Limited (NASDAQ:YDES - Get Free Report)'s stock price shot up 2.8% during mid-day trading on Monday . The company traded as high as $5.46 and last traded at $5.6150. 6,427 shares traded hands during trading, a decline of 75% from the average session volume of 25,456 shares. The stock had previously closed at $5.46.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on YDES. Wall Street Zen upgraded YD Bio from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Weiss Ratings restated a "sell (d+)" rating on shares of YD Bio in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Sell".
Check Out Our Latest Stock Report on YD Bio
YD Bio Stock Performance
The stock has a 50 day moving average price of $7.11.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC increased its position in YD Bio Limited (NASDAQ:YDES - Free Report) by 10.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 58,363 shares of the biotechnology company's stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned approximately 0.08% of YD Bio worth $711,000 as of its most recent filing with the Securities & Exchange Commission.
About YD Bio
(
Get Free Report)
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider YD Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and YD Bio wasn't on the list.
While YD Bio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
